中洪博元,湖南斯莱克 z-bo 2021-01-11 1263

　　On January 5, 2021, just after New Year’s Day, at the beginning of the new year, Mr. Jiang Bin, General Manager of Zvast-Bio, led the company’s R&D Director Dr. Yuan Yongming, CFO Ms. Fan Gailing and CRO Manager Yang Dong to Hunan SJA Laboratory Animal Co.，Ltd . and Hunan Anshengmei Pharmaceutical Research Institute Co., Ltd., Liang Huadong, general manager of Slack, and Du Liguo, general manager of Anshengmei Pharmaceutical Research Institute, warmly received Zvast-Bio and his party. The two parties carried out the whole industry from experimental animals to animal modeling and CRO services. The chain model cooperation reached a strategic cooperation intention, which opened the curtain for the two parties to show their grandeur in 2021.

　　General Manager Liang Huadong first welcomed the arrival of General Manager Jiang Bin and his party, and personally introduced Slack's development overview. Slack is invested and controlled by the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences. It has two production bases of 100 acres in Changsha Longping and Miluo Xinnong, with an annual supply capacity of 3 million SPF mice. The company also has 2,000 square meters of animal laboratories and functional laboratories that meet GLP standards, which can provide drug safety evaluation services.

Liang Huadong, General Manager of Hunan SJA Laboratory Animal Co.，Ltd

　　General Manager Jiang Bin thanked General Manager Liang Huadong for his thoughtful and meticulous reception, and focused on introducing the development trend of Zvast-Bio. In 2020, Zvast-bio has determined the strategy of taking disease animal models as its core advantage, insisting on scientific research services and CRO services as the industry track, and achieving an annual performance increase of more than 50%. Zvast-bio has prepared more than 150 disease animal models, and new models will be created every year in the future. Add 50 models to ensure that the model types are among the best in the country.

Jiang Bin, General Manager of  Zvast-Bio Biological

　　General Manager Jiang Bin believes that experimental animal models are an irreplaceable core biological resource in my country’s scientific research, biomedicine and health product research and development, and have important realities in improving my country’s independent innovation capabilities, maintaining national security, and developing the medical and health industry. Significance and broad market prospects. Especially in the face of the sudden outbreak of the new crown pneumonia at the end of 2019, the animal model of the new crown virus created by Chinese scientists has made significant contributions to the rapid development of drugs and vaccines in my country and the control of the epidemic.

　　 Zvast-bio responded to the call of the Party Central Committee to strengthen the hard core of science and technology. Aiming at the weak links of domestic disease animal models, it invested a large amount of funds for basic research and development. It has prepared more than 150 disease animal models and has become one of the top domestic companies in preparing disease animal models.

　　 In general, Zvast-bio is based in Jiangxi, with business facing the whole country, and has three core advantages:

　　 1. There are 150 kinds of disease animal models, which are increasing at a rate of 30-50 kinds every year, making it the best in the country.

    　 2. An industrial chain centered on model animals has been formed.

　　3. Established Zvast-Bio's own standardization and management system.

　　 General Manager Liang Huadong said: Zvast-Bio is developing very fast, and it is not easy to achieve 50% growth in performance in 2020. The market for scientific research services is high, and the requirements for the team, equipment and R&D technology are very high. Slack can further deepen cooperation with Zvast-Bio in the field of experimental animals.

Du Liguo, General Manager of Hunan Anshengmei Pharmaceutical Research Institute Co., Ltd.

Zvast-Bio visited Hunan Anshengmei Pharmaceutical Research Institute

　　Du Liguo, General Manager of Anshengmei Pharmaceutical Research Institute, introduced: The GLP certification of the Anshengmei Pharmaceutical Research Institute will undergo site modification in 2017, and the pre-experiment declaration will begin in 2018. The certificate will be approved in early 2021, and drug safety evaluation services can be carried out.

　　 The two parties agreed that the businesses of Zvast-Bio and Slack are highly complementary. Both parties can carry out strategic cooperation across the industry chain from experimental animal production to animal modeling and CRO business, and jointly expand and strengthen the experimental animal market and CRO business. The two parties agreed that upon reaching a strategic cooperation intention, their designated personnel will be responsible for implementing this cooperation.